Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 18 years of age or older~* Must currently be on ACE inhibitor therapy and have received a dose within 36 hours~* Presenting with ACEIA of the head/neck region within 12 hours after onset~* All females must have a negative urine pregnancy test prior to administration of the study drug. Those who have had a total hysterectomy, bilateral oophorectomy or are two years post-menopausal do not require a pregnancy test.~Exclusion Criteria:~* Hypersensitivity to ecallantide~* Pregnancy or breast feeding~* Patients who have had angioedema and were not concurrently on an ACE inhibitor~* Patients exhibiting urticaria~* Patients who are intubated or who have a tracheostomy related to the current episode of angioedema~* Opinion of the investigator that the patient would not be a good candidate~* Participation in another investigational study within 30 days prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ecallantide 10mg (Type: ACTIVE_COMPARATOR): Administered as one 3 mL SC injection containing 10 mg ecallantide and one 3 mL SC injection of matching placebo.
- placebo (Type: PLACEBO_COMPARATOR): Administered as two SC 3 mL injections
- ecallantide 60mg (Type: ACTIVE_COMPARATOR): Administered as two 3 mL SC injections, each containing 30 mg ecallantide
- ecallantide 30mg (Type: ACTIVE_COMPARATOR): Administered as one 3 mL SC injection containing 30 mg ecallantide and one 3 mL SC injection of matching placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).